Guided Capital Wealth Management LLC Purchases 1,775 Shares of Natera, Inc. (NASDAQ:NTRA)

Guided Capital Wealth Management LLC raised its position in Natera, Inc. (NASDAQ:NTRA - Free Report) by 15.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 13,069 shares of the medical research company's stock after purchasing an additional 1,775 shares during the quarter. Natera accounts for approximately 1.5% of Guided Capital Wealth Management LLC's holdings, making the stock its 21st largest holding. Guided Capital Wealth Management LLC's holdings in Natera were worth $1,848,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Smartleaf Asset Management LLC increased its position in shares of Natera by 50.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 657 shares of the medical research company's stock valued at $104,000 after acquiring an additional 220 shares during the last quarter. Steward Partners Investment Advisory LLC increased its position in shares of Natera by 1,328.0% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company's stock valued at $57,000 after acquiring an additional 332 shares during the last quarter. Teza Capital Management LLC acquired a new stake in shares of Natera in the fourth quarter valued at about $221,000. Townsquare Capital LLC acquired a new stake in shares of Natera in the fourth quarter valued at about $248,000. Finally, Global Retirement Partners LLC increased its position in shares of Natera by 55.0% in the fourth quarter. Global Retirement Partners LLC now owns 434 shares of the medical research company's stock valued at $69,000 after acquiring an additional 154 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company's stock.

Insiders Place Their Bets

In other Natera news, Director Gail Boxer Marcus sold 4,000 shares of the company's stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $164.44, for a total transaction of $657,760.00. Following the completion of the sale, the director now directly owns 5,704 shares in the company, valued at $937,965.76. This represents a 41.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Steven Leonard Chapman sold 9,563 shares of the company's stock in a transaction on Monday, March 31st. The stock was sold at an average price of $138.41, for a total value of $1,323,614.83. Following the sale, the chief executive officer now owns 212,541 shares of the company's stock, valued at $29,417,799.81. The trade was a 4.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 59,755 shares of company stock worth $8,898,589 over the last three months. Insiders own 7.60% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on NTRA shares. Royal Bank Of Canada started coverage on Natera in a research report on Thursday, March 13th. They issued an "outperform" rating and a $251.00 target price on the stock. Canaccord Genuity Group reissued a "buy" rating and set a $180.00 price target on shares of Natera in a research report on Wednesday, February 26th. Robert W. Baird boosted their price target on Natera from $183.00 to $188.00 and gave the stock an "outperform" rating in a research report on Friday, February 28th. Wall Street Zen downgraded Natera from a "hold" rating to a "sell" rating in a research report on Saturday, May 17th. Finally, UBS Group boosted their price target on Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a research report on Friday, May 9th. One research analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Natera has an average rating of "Moderate Buy" and a consensus price target of $184.63.

Natera Stock Up 0.5%

Shares of Natera stock traded up $0.88 on Friday, hitting $171.86. The stock had a trading volume of 1,516,357 shares, compared to its average volume of 1,417,173. The stock has a market cap of $23.47 billion, a price-to-earnings ratio of -116.91 and a beta of 1.74. The business's 50 day moving average is $157.00 and its two-hundred day moving average is $158.64. Natera, Inc. has a twelve month low of $92.14 and a twelve month high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.09. The business had revenue of $501.83 million during the quarter, compared to analysts' expectations of $446.68 million. Natera had a negative return on equity of 18.29% and a negative net margin of 10.36%. The firm's revenue for the quarter was up 36.5% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.56) earnings per share. As a group, equities analysts predict that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.